Cano Health Analyst Ratings
Cano Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | -47.37% | Citigroup | $4 → $0.8 | Downgrades | Buy → Neutral |
| 05/16/2023 | -34.21% | Piper Sandler | $0.5 → $1 | Maintains | Underweight |
| 05/12/2023 | 64.47% | Credit Suisse | → $2.5 | Reiterates | Neutral → Neutral |
| 01/06/2023 | -17.76% | UBS | $12 → $1.25 | Downgrades | Buy → Neutral |
| 01/05/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/13/2022 | -1.32% | B of A Securities | → $1.5 | Reinstates | → Underperform |
| 11/16/2022 | 228.95% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/10/2022 | 97.37% | Cowen & Co. | $10 → $3 | Downgrades | Outperform → Market Perform |
| 11/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/27/2022 | 228.95% | Credit Suisse | $10 → $5 | Downgrades | Outperform → Neutral |
| 09/07/2022 | 360.53% | Truist Securities | → $7 | Initiates Coverage On | → Hold |
| 08/10/2022 | 163.16% | Piper Sandler | $4 → $4 | Maintains | Underweight |
| 06/24/2022 | 426.32% | Raymond James | → $8 | Initiates Coverage On | → Outperform |
| 06/15/2022 | 294.74% | B of A Securities | $8 → $6 | Downgrades | Buy → Neutral |
| 05/11/2022 | 557.89% | Credit Suisse | $13 → $10 | Maintains | Outperform |
| 05/11/2022 | 163.16% | Piper Sandler | $5 → $4 | Maintains | Underweight |
| 05/10/2022 | 426.32% | Citigroup | $10 → $8 | Maintains | Buy |
| 05/03/2022 | 426.32% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 04/20/2022 | 886.84% | UBS | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | 228.95% | Piper Sandler | $8.5 → $5 | Downgrades | Neutral → Underweight |
| 03/16/2022 | 755.26% | Credit Suisse | $15 → $13 | Maintains | Outperform |
| 11/10/2021 | 755.26% | Piper Sandler | $11 → $13 | Maintains | Neutral |
| 10/20/2021 | 1018.42% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 10/19/2021 | 623.68% | Piper Sandler | → $11 | Initiates Coverage On | → Neutral |
| 10/01/2021 | 1150% | Wolfe Research | → $19 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 1215.79% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 09/10/2021 | 1084.21% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 1084.21% | Credit Suisse | → $18 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | -47.37% | 花旗集團 | 4 美元 → 0.8 美元 | 降級 | 買入 → 中性 |
| 05/16/2023 | -34.21% | 派珀·桑德勒 | 0.5 美元 → 1 美元 | 維護 | 體重不足 |
| 05/12/2023 | 64.47% | 瑞士信貸 | → 2.5 美元 | 重申 | 中性 → 中性 |
| 01/06/2023 | -17.76% | 瑞銀（UBS） | 12 美元 → 1.25 美元 | 降級 | 買入 → 中性 |
| 01/05/2023 | — | 沃爾夫研究 | 降級 | 跑贏大盤 → 同行表現 | |
| 12/13/2022 | -1.32% | B of A 類證券 | → 1.5 美元 | 恢復 | → 表現不佳 |
| 11/16/2022 | 228.95% | 花旗集團 | 7 美元 → 5 美元 | 維護 | 購買 |
| 2022 年 10 月 11 日 | 97.37% | Cowen & Co. | 10 美元 → 3 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 2022 年 10 月 11 日 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
| 10/27/2022 | 228.95% | 瑞士信貸 | 10 美元 → 5 美元 | 降級 | 跑贏大盤 → 中性 |
| 09/07/2022 | 360.53% | 信託證券 | → 7 美元 | 啓動覆蓋開啓 | → 按住 |
| 08/10/2022 | 163.16% | 派珀·桑德勒 | 4 美元 → 4 美元 | 維護 | 體重不足 |
| 2022 年 6 月 24 日 | 426.32% | 雷蒙德·詹姆 | → 8 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 06/15/2022 | 294.74% | B of A 類證券 | 8 美元 → 6 美元 | 降級 | 買入 → 中性 |
| 05/11/2022 | 557.89% | 瑞士信貸 | 13 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 05/11/2022 | 163.16% | 派珀·桑德勒 | 5 美元 → 4 美元 | 維護 | 體重不足 |
| 05/10/2022 | 426.32% | 花旗集團 | 10 美元 → 8 美元 | 維護 | 購買 |
| 05/03/2022 | 426.32% | B of A 類證券 | → 8 美元 | 啓動覆蓋開啓 | → 購買 |
| 04/20/2022 | 886.84% | 瑞銀（UBS） | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 04/06/2022 | 228.95% | 派珀·桑德勒 | 8.5 美元 → 5 美元 | 降級 | 中性 → 體重不足 |
| 2022 年 3 月 16 日 | 755.26% | 瑞士信貸 | 15 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 11/10/2021 | 755.26% | 派珀·桑德勒 | 11 美元 → 13 美元 | 維護 | 中立 |
| 2021 年 10 月 20 日 | 1018.42% | 傑富瑞 | → 17 美元 | 啓動覆蓋開啓 | → 購買 |
| 10/19/2021 | 623.68% | 派珀·桑德勒 | → 11 美元 | 啓動覆蓋開啓 | → 中立 |
| 2021 年 1 月 10 日 | 1150% | 沃爾夫研究 | → 19 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 09/21/2021 | 1215.79% | 花旗集團 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 10 月 9 日 | 1084.21% | Cowen & Co. | → 18 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 2 月 8 日 | 1084.21% | 瑞士信貸 | → 18 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
What is the target price for Cano Health (CANO)?
Cano Health（CANO）的目標價格是多少？
The latest price target for Cano Health (NYSE: CANO) was reported by Citigroup on August 11, 2023. The analyst firm set a price target for $0.80 expecting CANO to fall to within 12 months (a possible -47.37% downside). 11 analyst firms have reported ratings in the last year.
花旗集團於2023年8月11日公佈了Cano Health（紐約證券交易所代碼：CANO）的最新目標股價。這家分析公司將目標股價定爲0.80美元，預計CANO將在12個月內跌至-47.37％（可能下跌-47.37％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Cano Health (CANO)?
分析師對Cano Health（CANO）的最新評級是多少？
The latest analyst rating for Cano Health (NYSE: CANO) was provided by Citigroup, and Cano Health downgraded their neutral rating.
Cano Health（紐約證券交易所代碼：CANO）的最新分析師評級由花旗集團提供，Cano Health下調了中性評級。
When is the next analyst rating going to be posted or updated for Cano Health (CANO)?
Cano Health（CANO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Cano Health的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Cano Health 的最後一次評級是在2023年8月11日提交的，因此你應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Cano Health (CANO) correct?
分析師對 Cano Health (CANO) 的評級正確嗎？
While ratings are subjective and will change, the latest Cano Health (CANO) rating was a downgraded with a price target of $4.00 to $0.80. The current price Cano Health (CANO) is trading at is $1.52, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Cano Health（CANO）評級被下調，目標股價爲4.00美元至0.80美元。Cano Health（CANO）目前的交易價格爲1.52美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。